Sanofi reported a strong performance in Q3, staging a gradual recovery – from a weak Q1 to a mixed Q2 to a strong Q3, surpassing both our as well as the consensus expectations. Net sales grew by 6.3% at CER to €9.39bn, on the back of a strong biotech business and a recovery in vaccines, while consumer health delivered a steady 4% growth. NB All sales growth numbers at CER unless specified otherwise. Geographically, emerging markets (+10.4%) ruled the quarter across the business seg
01 Nov 2018
Emerging markets boost vaccines and consumer health as Dupixent recovers
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Emerging markets boost vaccines and consumer health as Dupixent recovers
Sanofi reported a strong performance in Q3, staging a gradual recovery – from a weak Q1 to a mixed Q2 to a strong Q3, surpassing both our as well as the consensus expectations. Net sales grew by 6.3% at CER to €9.39bn, on the back of a strong biotech business and a recovery in vaccines, while consumer health delivered a steady 4% growth. NB All sales growth numbers at CER unless specified otherwise. Geographically, emerging markets (+10.4%) ruled the quarter across the business seg